8-K: Current report filing
Published on January 7, 2010
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF
1934
DATE
OF REPORT (DATE OF EARLIEST EVENT REPORTED)
January
7, 2010
NOVELOS
THERAPEUTICS, INC.
(EXACT
NAME OF REGISTRANT AS SPECIFIED IN CHARTER)
|
DELAWARE
|
333-119366
|
04-3321804
|
||
|
(STATE
OR OTHER JURISDICTION
|
(COMMISSION
|
(IRS
EMPLOYER
|
||
|
OF
INCORPORATION)
|
FILE
NUMBER)
|
IDENTIFICATION
NO.)
|
One
Gateway Center, Suite 504, Newton, Massachusetts 02458
(ADDRESS
OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
REGISTRANT’S
TELEPHONE NUMBER, INCLUDING AREA CODE: (617) 244-1616
NOT
APPLICABLE
(FORMER
NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)
CHECK THE
APPROPRIATE BOX BELOW IF THE FORM 8-K FILING IS INTENDED TO SIMULTANEOUSLY
SATISFY THE FILING OBLIGATION OF THE REGISTRANT UNDER ANY OF THE FOLLOWING
PROVISIONS:
|
o
|
WRITTEN
COMMUNICATIONS PURSUANT TO RULE 425 UNDER THE SECURITIES ACT (17 CFR
230.425)
|
|
|
o
|
SOLICITING
MATERIAL PURSUANT TO RULE 14a-12 UNDER THE EXCHANGE ACT (17 CFR
240.14a-12)
|
|
|
o
|
PRE-COMMENCEMENT
COMMUNICATIONS PURSUANT TO RULE 14d-2(b) UNDER THE EXCHANGE ACT (17 CFR
240.14d-2(b))
|
|
|
o
|
PRE-COMMENCEMENT
COMMUNICATIONS PURSUANT TO RULE 13e-4(c) UNDER THE EXCHANGE ACT (17 CFR
240.13e-4(c))
|
ITEM
7.01 REGULATION FD
DISCLOSURE
A copy of
the press release issued by us on January 7, 2010 announcing the occurrence of
the 725th event
in our pivotal phase 3 lung cancer trial is furnished as Exhibit 99.1 and is
incorporated by reference in this Item.
ITEM 9.01
FINANCIAL STATEMENTS
AND EXHIBITS
(c)
Exhibits
|
Number
|
Title
|
|
|
99.1
|
Press
Release dated January 7, 2010 entitled “Novelos Therapeutics Reaches
725th
Event in Pivotal Phase 3 Lung Cancer
Trial.”
|
- 2
- -
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Dated:
January 7, 2010
|
NOVELOS
THERAPEUTICS, INC.
|
|||
|
By:
|
/s/
Harry S. Palmin
|
|||
|
Harry
S. Palmin
|
||||
|
President
and Chief Executive Officer
|
||||
- 3
- -
EXHIBIT
INDEX
|
Number
|
Title
|
|
|
99.1
|
Press
Release dated January 7, 2010 entitled “Novelos Therapeutics Reaches
725th
Event in Pivotal Phase 3 Lung Cancer
Trial.”
|
- 4
- -